还是算了
Lv4
580 积分
2023-09-01 加入
-
Comprehensive analysis of kinase inhibitor selectivity
13天前
已完结
-
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
16天前
已完结
-
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
18天前
已完结
-
Chronic Spontaneous Urticaria in Belgium: Deciphering the Clinical Profile and Treatment of Patients Visiting an Urban City Immunology Department
20天前
已关闭
-
Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions
20天前
已关闭
-
Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab
28天前
已完结
-
A Review of Dupilumab-Induced Adverse Events to Dermatologists and the Potential Pathogenesis in the Treatment of Atopic Dermatitis
28天前
已完结
-
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
28天前
已完结
-
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors
1个月前
已完结
-
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
1个月前
已完结